Targeting the Calmodulin-Regulated ErbB/Grb7 Signaling Axis in Cancer Therapy

Authors

  • Antonio Villalobo Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas & Universidad Autónoma de Madrid
  • Irene García-Palmero Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas & Universidad Autónoma de Madrid
  • Silviya R. Stateva Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas & Universidad Autónoma de Madrid
  • Karim Jellali Centre of Biotechnology of Sfax, Sidi Mansour Road Km 6, Sfax, Tunisia

DOI:

https://doi.org/10.18433/J3V59V

Abstract

Signal transduction pathways essential for the survival and viability of the cell and that frequently present aberrant expression or function in tumors are attractive targets for pharmacological intervention in human cancers. In this short review we will describe the regulation exerted by the calcium-receptor protein calmodulin (CaM) on signaling routes involving the family of ErbB receptors - highlighting the epidermal growth factor receptor (EGFR/ErbB1) and ErbB2 - and the adaptor protein Grb7, a downstream signaling component of these receptors. The signaling mechanism of the ErbB/Grb7 axis and the regulation exerted by CaM on this pathway will be described. We will present a brief overview of the current efforts to inhibit the hyperactivity of ErbB receptors and Grb7 in tumors. The currently available information on targeting the CaM-binding site of these signaling proteins will be analyzed, and the pros and cons of directly targeting CaM versus the CaM-binding domain of the ErbB receptors and Grb7 as potential anti-cancer therapy will be discussed. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Downloads

Download data is not yet available.

Author Biographies

Antonio Villalobo, Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas & Universidad Autónoma de Madrid

Department of Cancer Biology Research Professor CSIC

Irene García-Palmero, Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas & Universidad Autónoma de Madrid

Department of Cancer Biology Research Associate

Silviya R. Stateva, Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas & Universidad Autónoma de Madrid

Department of Cancer Biology PhD Student

Karim Jellali, Centre of Biotechnology of Sfax, Sidi Mansour Road Km 6, Sfax, Tunisia

Department of Cancer Biology PhD Student

Downloads

Published

2013-04-30

How to Cite

Villalobo, A., García-Palmero, I., Stateva, S. R., & Jellali, K. (2013). Targeting the Calmodulin-Regulated ErbB/Grb7 Signaling Axis in Cancer Therapy. Journal of Pharmacy & Pharmaceutical Sciences, 16(2), 177–189. https://doi.org/10.18433/J3V59V

Issue

Section

CLOSED. Special Issue - Chief Guest Editor: Basil D Roufogalis; Co-Guest Editors: Emanuel Strehler & Srinivas Nammi